William J. Towner
Kaiser Permanente
90 Papers
556 Citations
William J. Towner is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 35, co-authored 79 publications. Previous affiliations of William J. Towner include Goethe University Frankfurt & Queen Mary University of London.
Chat about Author
Papers
Remdesivir for 5 or 10 Days in Patients with Severe Covid-19.
Jason D Goldman,David C. Lye,David S.C. Hui,Kristen M. Marks,Raffaele Bruno,Rocio Montejano,Christoph D. Spinner,Massimo Galli,Mi Young Ahn,Ronald Nahass,Yao Shen Chen,Devi SenGupta,Robert H. Hyland,Anu Osinusi,Huyen Cao,Christiana Blair,Xuelian Wei,Anuj Gaggar,Diana M. Brainard,William J. Towner,Jose Muñoz,Kathleen M. Mullane,Francisco M. Marty,Karen T. Tashima,George A. Diaz,Aruna Subramanian +25 more
TL;DR: In patients with severe Covid-19 not requiring mechanical ventilation, a randomized, open-label, phase 3 trial involving hospitalized patients with confirmed SARS-CoV-2 infection, oxygen saturation of 94% or less while they were breathing ambient air, and radiologic evidence of pneumonia, the magnitude of benefit cannot be determined.
Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection
Jordan J. Feld,Ira M. Jacobson,Christophe Hézode,Tarik Asselah,Peter Ruane,Norbert Gruener,Armand Abergel,Alessandra Mangia,Ching-Lung Lai,Henry Lik Yuen Chan,Francesco Mazzotta,Christophe Moreno,Eric M. Yoshida,Stephen D. Shafran,William J. Towner,Tram T. Tran,John McNally,Anu Osinusi,Evguenia S. Svarovskaia,Yanni Zhu,Diana M. Brainard,John G. McHutchison,Kosh Agarwal,Stefan Zeuzem +23 more
TL;DR: Once-daily sofosbuvir-velpatasvir for 12 weeks provided high rates of sustained virologic response among both previously treated and untreated patients infected with HCV genotype 1, 2, 4, 5, or 6, including those with compensated cirrhosis.
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
Graham R. Foster,Nezam H. Afdhal,Stuart K. Roberts,Norbert Bräu,E.J. Gane,S. Pianko,E.J. Lawitz,Alexander J. Thompson,Mitchell L. Shiffman,Curtis L Cooper,William J. Towner,Brian Conway,Peter Ruane,M. Bourliere,Tarik Asselah,Thomas Berg,S. Zeuzem,William Rosenberg,Kosh Agarwal,Catherine A.M. Stedman,Hongmei Mo,Hadas Dvory-Sobol,Lingling Han,Jing Wang,John McNally,Anu Osinusi,Diana M. Brainard,John G. McHutchison,Francesco Mazzotta,Tram T. Tran,Stuart C. Gordon,Keyur Patel,Nancy Reau,Alessandra Mangia,Mark S. Sulkowski +34 more
TL;DR: Among patients with HCV genotype 2 or 3 with or without previous treatment, including those with compensated cirrhosis, 12 weeks of treatment with sofosbuvir-velpatasvir resulted in rates of sustained virologic response that were superior to those with standard treatment withSofosBuvir-ribavirin.
838
Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial.
Adriano Lazzarin,Thomas B. Campbell,Bonaventura Clotet,Margaret Johnson,Christine Katlama,Arend Moll,William J. Towner,Benoit Trottier,Monika Peeters,Johan Vingerhoets,Goedele De Smedt,Benny Baeten,Greet Beets,Rekha Sinha,Brian Woodfall +14 more
TL;DR: In treatment-experienced patients with NNRTI resistance, treatment with TMC 125 achieved better virological suppression at week 24 than did placebo, and the safety and tolerability profile of TMC125 was generally comparable with placebo.
526
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1
Susanna Naggie,Curtis Cooper,Michael S. Saag,Kimberly A. Workowski,Peter Ruane,William J. Towner,Kristen M. Marks,Anne F Luetkemeyer,Rachel Baden,Rachel Baden,Paul E. Sax,E.J. Gane,Jorge Santana-Bagur,Luisa M. Stamm,Jenny C. Yang,Polina German,Hadas Dvory-Sobol,Liyun Ni,Phillip S. Pang,John G. McHutchison,Catherine A.M. Stedman,Javier O Morales-Ramirez,Norbert Bräu,Norbert Bräu,Dushyantha Jayaweera,Amy E. Colson,Pablo Tebas,David Wong,Douglas T. Dieterich,Mark S. Sulkowski +29 more
TL;DR: Ledipasvir and sofosbuvir as a single fixed-dose combination for 12 weeks provided high rates of sustained virologic response in patients coinfected with HIV-1 and HCV genotype 1 or 4.